France
Tridek-One is a French biotechnology startup founded in 2018, specializing in the development of first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company's focus on anti-CD31 agonistic mAbs presents the potential to offer targeted immunomodulatory activity with a favorable safety profile in areas characterized by high unmet clinical needs.
The recent €16.00M Venture Round investment on 15 September 2022, with participation from leading European investors including Advent Life Sciences, Bpifrance, Bioqube Ventures, Kinled Holding Ltd, AdBio partners, and Pureos Bioventures, signifies significant support and confidence in Tridek-One's innovative approach and potential impact in the field of biotechnology and healthcare.
With a strong foundation in place and an experienced management team, Tridek-One is well-positioned to advance its discovery program, targeting additional ITIM receptors and further leveraging its expertise in inhibitory checkpoint receptor modulation and agonistic monoclonal antibodies engineering. This strategic direction reinforces the company's commitment to advancing novel therapies for the benefit of patients with autoimmune and inflammatory diseases.
